Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10924MR)

This product GTTS-WQ10924MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10924MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ178MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ9940MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ6757MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ12714MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ11992MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ11888MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ3664MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8929MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW